» Articles » PMID: 35116992

Clinicopathologic Factors Associated with Short-term Survival in Advanced Epithelial Ovarian Cancer

Overview
Specialty Oncology
Date 2022 Feb 4
PMID 35116992
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy, and there is a deficiency of information in the literature on the early recognition of short-term survivor (STS). This study aimed to identify the clinicopathological factors associated with STS in late-stage EOC and to establish a predictive model to identify STS.

Methods: Selected patients with International Federation of Gynecology and Obstetrics (FIGO) stage III or IV EOC were included in the study, and a retrospective analysis was performed. The characteristics of the patients who survived not more than 2 years (STS) were compared to those who survived at least 2 years (defined as long-term survivors, LTS). Binary logistic regression and receiver operating characteristic curve (ROC) were used to identify the independent prognostic factors associated with EOC and assess the predictive accuracy for STS.

Results: We identified 254 patients with advanced EOC including 57 STS and 197 LTS. A univariate analysis revealed that STS had a tendency to have omental metastasis and larger tumor size, to be platinum resistant, to have non-serous histology, to undergo suboptimal cytoreduction, to have comorbidity, and to undergo primary chemotherapy less than 6 courses. Binary regression analysis revealed that tumor size (P=0.033), platinum resistance (P<0.001), non-serous histology (P=0.048) and number of primary chemotherapy (P=0.028) were significant independent predictors of STS. A developed predictive model using these predictors had an AUC =0.831; platinum resistance alone had an AUC =0.732.

Conclusions: Tumor size, omental metastasis, platinum resistance, non-serous histology, and number of primary chemotherapy are predictors associated with STS when controlling other confounding factors. Tumor size and omental metastasis may be considered novel, important prognostic factors for advanced EOC patients. Platinum resistance was the most important prognosticator for STS; hence, more work is needed for the early identification and treatment of these EOC patients.

Citing Articles

Synergistic antitumor effect of liposomal-based formulations of olaparib and topotecan in primary epithelial ovarian cancer cells.

Romaniuk-Drapala A, Skupin-Mrugalska P, Garbuzenko O, Hatefi A, Minko T Cancer Cell Int. 2024; 24(1):285.

PMID: 39135053 PMC: 11320834. DOI: 10.1186/s12935-024-03469-0.


Detection and analysis of multiple biomarkers in ovarian cancer: clinical significance in diagnosis, treatment, and prognosis evaluation.

Ji R, Li Y, He C, Zhu X, He A, Lu Y Gland Surg. 2021; 9(6):2175-2186.

PMID: 33447568 PMC: 7804549. DOI: 10.21037/gs-20-811.

References
1.
Riester M, Wei W, Waldron L, Culhane A, Trippa L, Oliva E . Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst. 2014; 106(5). PMC: 4580556. DOI: 10.1093/jnci/dju048. View

2.
Bandera E, Lee V, Qin B, Rodriguez-Rodriguez L, Powell C, Kushi L . Impact of body mass index on ovarian cancer survival varies by stage. Br J Cancer. 2017; 117(2):282-289. PMC: 5520512. DOI: 10.1038/bjc.2017.162. View

3.
Winter 3rd W, Maxwell G, Tian C, Carlson J, Ozols R, Rose P . Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007; 25(24):3621-7. DOI: 10.1200/JCO.2006.10.2517. View

4.
Slaughter K, Holman L, Thomas E, Gunderson C, Lauer J, Ding K . Primary and acquired platinum-resistance among women with high grade serous ovarian cancer. Gynecol Oncol. 2016; 142(2):225-30. DOI: 10.1016/j.ygyno.2016.05.020. View

5.
Nowicka A, Marini F, Solley T, Elizondo P, Zhang Y, Sharp H . Human omental-derived adipose stem cells increase ovarian cancer proliferation, migration, and chemoresistance. PLoS One. 2013; 8(12):e81859. PMC: 3847080. DOI: 10.1371/journal.pone.0081859. View